{"id":600418,"date":"2022-05-17T18:54:01","date_gmt":"2022-05-17T18:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=600418"},"modified":"2022-05-17T18:54:01","modified_gmt":"2022-05-17T18:54:01","slug":"soft-tissue-sarcoma-market-to-exhibit-remarkable-growth-by-2032-analyzes-delveinsight-epizyme-eli-lilly-philogen-karyopharm-therapeutics-genentech-boehringer-ingelheim-eisai-daiichi-sankyo","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/soft-tissue-sarcoma-market-to-exhibit-remarkable-growth-by-2032-analyzes-delveinsight-epizyme-eli-lilly-philogen-karyopharm-therapeutics-genentech-boehringer-ingelheim-eisai-daiichi-sankyo_600418.html","title":{"rendered":"Soft tissue sarcoma Market to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Epizyme, Eli Lilly, Philogen, Karyopharm Therapeutics, Genentech, Boehringer Ingelheim, Eisai, Daiichi Sankyo"},"content":{"rendered":"
\n
\"Soft<\/a><\/div>\n
\n
Soft tissue sarcoma Market<\/div>\n<\/div>\n<\/div>\n

Soft tissue sarcoma<\/strong> (STS) is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). STS are a rare and heterogeneous group of tumors, arising in connective tissues embryologically derived from the mesenchyme. Soft tissue sarcomas (STSs) comprises entities defined by the World Health Organization (WHO) classification based on a combination of distinctive morphological, immune-histochemical and molecular features.<\/p>\n

 <\/p>\n

DelveInsight added a new report titled “Soft Tissue Sarcoma Market<\/strong><\/a> Insight, Epidemiology and Market Forecast-2032<\/strong>” to its Market report portfolio. The report provides Soft Tissue Sarcoma (STS) Market Analysis, Market Size Forecast, detailed Epidemiology analysis and forecast, information related to Leading Companies along with the Competitive Analysis.<\/p>\n

 <\/p>\n

Some of the key highlights of the Soft Tissue Sarcoma market report are:-<\/strong><\/p>\n

    \n
  1. Sarcomas are uncommon cancers that can affect any part of the body, on the inside or outside, including the muscle, bone, tendons, blood vessels and fatty tissues. 15 people are diagnosed with sarcoma every day in the UK. That’s about 5,300 people a year.<\/li>\n
  2. Among all the seven major markets, the United States accounts for the highest number of Soft Tissue Sarcoma cases.<\/li>\n
  3. In the European countries, Germany had the highest Soft Tissue Sarcoma incident population with followed by Italy.<\/li>\n
  4. The current Soft Tissue Sarcoma <\/em>market size is mainly attributed by Votrient, Yondelis, Halaven and various Anthracycline and non-Anthracycline regimens. <\/li>\n
  5. The Soft Tissue Sarcoma market size is increasing with a significant CAGR of 6.47%<\/em><\/strong> during the forecast period (2017-30) for 7MM.<\/li>\n
  6. Sarcoma survival rates have been very gradually increasing over the last two decades in the UK. Almost eight in 10 people (78%) diagnosed with sarcoma in the UK will live up to a year. The average percentage of people living three years after being diagnosed with sarcoma in the UK is 64.5%. The five-year survival rate for sarcoma is 55%.<\/li>\n<\/ol>\n

     <\/p>\n

    Get a sample report on Soft Tissue Sarcoma Market: <\/em><\/strong>https:\/\/www.delveinsight.com\/report-store\/soft-tissue-sarcoma-market<\/a><\/strong><\/p>\n

     <\/p>\n

    Key Benefits of the Report:<\/strong><\/p>\n

      \n
    1. Soft Tissue Sarcoma Market report covers a descriptive overview and comprehensive insight of the Soft Tissue Sarcoma epidemiology and Soft Tissue Sarcoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/li>\n
    2. Soft Tissue Sarcoma market report provides insights on the current and emerging therapies.<\/li>\n
    3. Soft Tissue Sarcoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/li>\n
    4. Soft Tissue Sarcoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Soft Tissue Sarcoma market.<\/li>\n<\/ol>\n

       <\/p>\n

      Soft-tissue sarcoma<\/strong> are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). Soft tissue sarcoma epidemiology is segmented by:<\/strong><\/p>\n